Pfizer (NYSE:PFE) Stock Falls 1.5% - Time to Sell?

Key Points

• Pfizer shares fell 1.5% to about $28.10, while trading volume was roughly 27% below the average session volume.
• Positive Phase 2 results for tilrekimig, an investigational atopic dermatitis treatment, boosted optimism about Pfizer’s pipeline and efforts to offset post-pandemic revenue declines.
• Risks remain significant: analysts’ consensus rating is “Hold,” with an average price target of $28.39, while slow growth, valuation concerns and more than $22 billion in potential revenue exposure from patent expirations weigh on the outlook.

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) traded down 1.5% during trading on Thursday. The stock traded as low as $28.08 and last traded at $28.0990. Approximately 29,620,346 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 40,696,957 shares. The stock had previously closed at $28.52.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 2 results for tilrekimig: Pfizer reported that its investigational atopic dermatitis treatment met its primary endpoint. Across all tested doses, significantly more patients achieved at least a 75% reduction in disease severity after 16 weeks versus placebo. The data support further development of tilrekimig and could strengthen Pfizer’s pipeline beyond its mature products. Pfizer’s Tilrekimig Phase 2 Study
• Positive Sentiment: Pipeline optimism remains a potential catalyst: The positive eczema data add to investor interest in new-drug opportunities as Pfizer works to offset revenue pressure from its post-pandemic portfolio and upcoming patent losses.
• Neutral Sentiment: Peer-focused trading limited a company-specific move: Pfizer was largely overshadowed by developments at Moderna and BioNTech. Moderna rose despite a Citigroup sell rating, while investors continued debating whether biotechnology pipeline potential justifies elevated valuations across the group. Moderna, BioNTech and Pfizer Trading
• Neutral Sentiment: Income appeal remains part of the investment case: Pfizer continues to attract attention from dividend-focused investors because of its roughly 6% yield, although higher Treasury yields make dividend stocks compete with relatively safer fixed-income alternatives. Patent-cliff risks remain central to the sustainability debate.
• Negative Sentiment: Valuation and growth concerns: A recent comparison argued that Pfizer trades at a higher valuation than some large pharmaceutical peers despite having the weakest sales growth among the companies reviewed. That raises questions about whether the stock’s valuation adequately reflects its slower growth outlook. Pfizer Valuation Compared With Rivals
• Negative Sentiment: Patent-expiration risk persists: Pfizer and Bristol Myers Squibb each face more than $22 billion in revenue exposure from drugs losing U.S. exclusivity, reinforcing concerns about future earnings, cash flow and dividend coverage. Pfizer and Bristol Myers Squibb Patent Cliff

Analysts Set New Price Targets

Several equities analysts have commented on PFE shares. HSBC lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research report on Thursday, September 10th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. BMO Capital Markets cut their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, July 13th. Weiss Ratings raised shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. Finally, Royal Bank Of Canada upgraded shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of "Hold" and an average price target of $28.39.

Pfizer Price Performance

The business's 50 day moving average is $27.28 and its two-hundred day moving average is $26.46. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm has a market capitalization of $160.16 billion, a PE ratio of 36.97, a price-to-earnings-growth ratio of 1.93 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company earned $0.78 earnings per share. The business's revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE purchased a new stake in Pfizer in the 2nd quarter worth approximately $1,049,602,000. BlackRock Inc. raised its position in shares of Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after buying an additional 31,412,883 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Pfizer by 38.9% during the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company's stock valued at $1,208,023,000 after buying an additional 13,581,757 shares during the period. Nykredit A S purchased a new position in Pfizer during the second quarter worth about $205,774,000. Finally, Capital World Investors raised its holdings in shares of Pfizer by 51.5% in the 4th quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company's stock valued at $533,704,000 after acquiring an additional 7,287,194 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.